Thyroid Hormones in ADPKD (REORIENTED)

Mario Negri Institute for Pharmacological Research

Status: Completed

Conditions: Autosomal Dominant Polycystic Kidney

Treatments: Other: Blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT05646420

REORIENTED

Details and patient eligibility

About

Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic, rare and life-threatening disease, characterized by the pathological formation of multiple fluid-filled cysts that arise from renal tubules and alter kidney architecture and function. In most patients, the progressive deterioration of renal function ultimately leads to end-stage kidney disease (ESKD) and the need for dialysis or kidney transplantation.

Save the conventional anti-hypertensive strategies, there are currently two disease-specific treatments for ADPKD (Tolvaptan and Octreotide-LAR). However, these drugs are only available to patients at high risk of progression to ESKD, while a remarkable number of ADPKD patients progress to ESKD despite the treatments.

Cyst formation in ADPKD is determined by mutations in two genes encoding two transmembrane proteins: polycystin1 and polycystin2. The pathogenesis of the disease involves a series of phenotypic alterations, including the de-differentiation of epithelial cells, uncontrolled proliferation and abnormal secretion of fluids in the cysts, metabolic remodeling, all phenomena that lead to the progressive loss of renal structure and function . Therefore, to try to investigate the mechanisms of the disease, the investigators should go in search of pleiotropic molecules capable of simultaneously modulating structure, function and metabolism.

Research done so far suggests that thyroid hormones (TH) may also act as pleiotropic modulators in the patho-biology of ADPKD. TH signals play a crucial role in the regulation of cell de-differentiation and cell cycle reactivation, as well as in the metabolism and evolution of cardiac and renal diseases. Interestingly, changes in TH levels have been detected in approximately 80% of patients with chronic renal failure (CKD), whereas patients with ADPKD show a higher incidence of clinical and subclinical hypothyroidism. Despite these evidences, the ability of TH to modulate anti-cystogenic and renoprotective processes in ADPKD has not yet been studied.

The objective of this study is to determine the levels of THs in the serum of ADPKD patients with normal renal function and mild, moderate or severe renal dysfunction, and to correlate them with renal functional parameters.

Enrollment: 91 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male and female ≥18 years old;
2. Diagnosis of ADPKD based on renal ultrasonography or genetic test;
3. Written informed consent

Exclusion criteria

1. Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement
2. Patient with hypothyroidism treated with drug therapy
3. Active treatment with Tolvaptan and/or Octreotide-LAR;
4. Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids;
5. Active malignancy or acute or chronic inflammatory disease, HIV;
6. Dialysis or kidney transplantation;
7. Diabetes mellitus;
8. Hypocaloric diet or current dietary approaches to obtain weight loss.
9. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures.

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

91 participants in 1 patient group

ADPKD patients

Experimental group

Description:

The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test. Specifically, five groups of patients will be identified according to KDIGO classification: * 18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage * 18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage * 18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage * 18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage * 18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage.

Treatment:

Other: Blood sampling